Merck & Co., Inc.'s Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study

BOSTON--(BUSINESS WIRE)--Merck & Co., Inc. today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo. In addition, the efficacy results for telcagepant 300 mg were similar to the highest recommended dose of zolmitriptan,1 an approved migraine therapy, with a lower incidence of adverse events associated with telcagepant in this study. The new data were presented here at the American Headache Society (AHS) annual meeting.